PL4255442T3 - Inhibitor jak z analogiem witaminy d do leczenia chorób skóry - Google Patents

Inhibitor jak z analogiem witaminy d do leczenia chorób skóry

Info

Publication number
PL4255442T3
PL4255442T3 PL21841055.3T PL21841055T PL4255442T3 PL 4255442 T3 PL4255442 T3 PL 4255442T3 PL 21841055 T PL21841055 T PL 21841055T PL 4255442 T3 PL4255442 T3 PL 4255442T3
Authority
PL
Poland
Prior art keywords
vitamin
analog
treatment
skin diseases
jak inhibitor
Prior art date
Application number
PL21841055.3T
Other languages
English (en)
Inventor
Paul Smith
Zheng Zhang
Melissa PARKER
James Fidge
Original Assignee
Incyte Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corporation filed Critical Incyte Corporation
Publication of PL4255442T3 publication Critical patent/PL4255442T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL21841055.3T 2020-12-04 2021-12-03 Inhibitor jak z analogiem witaminy d do leczenia chorób skóry PL4255442T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121531P 2020-12-04 2020-12-04
US202163199876P 2021-01-29 2021-01-29
PCT/US2021/061744 WO2022120131A1 (en) 2020-12-04 2021-12-03 Jak inhibitor with a vitamin d analog for treatment of skin diseases

Publications (1)

Publication Number Publication Date
PL4255442T3 true PL4255442T3 (pl) 2025-09-01

Family

ID=80112060

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21841055.3T PL4255442T3 (pl) 2020-12-04 2021-12-03 Inhibitor jak z analogiem witaminy d do leczenia chorób skóry

Country Status (24)

Country Link
US (2) US12005067B2 (pl)
EP (2) EP4255442B1 (pl)
JP (1) JP7847143B2 (pl)
KR (1) KR20230128472A (pl)
AU (1) AU2021390533A1 (pl)
CA (1) CA3204186A1 (pl)
CL (1) CL2023001603A1 (pl)
DK (1) DK4255442T3 (pl)
ES (1) ES3025481T3 (pl)
FI (1) FI4255442T3 (pl)
HR (1) HRP20250528T1 (pl)
HU (1) HUE071614T2 (pl)
IL (1) IL303410A (pl)
LT (1) LT4255442T (pl)
MA (1) MA62453B1 (pl)
MD (1) MD4255442T2 (pl)
MX (1) MX2023006638A (pl)
PL (1) PL4255442T3 (pl)
PT (1) PT4255442T (pl)
RS (1) RS66785B1 (pl)
SI (1) SI4255442T1 (pl)
SM (1) SMT202500205T1 (pl)
WO (1) WO2022120131A1 (pl)
ZA (1) ZA202306521B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190156A (es) 2013-05-17 2019-05-16 Incyte Corp Derivados de bipirazol como inhibidores jak
CA3091339A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
US20230414620A1 (en) * 2020-10-02 2023-12-28 Incyte Corporation Topical ruxolitinib for treating lichen planus
IL303238A (en) 2020-12-08 2023-07-01 Incyte Corp Jak1 pathway inhibitors for the treatment of vitiligo
US20240075040A1 (en) * 2021-05-03 2024-03-07 Incyte Corporation Ruxolitinib for the treatment of prurigo nodularis
CN115869321A (zh) * 2021-09-28 2023-03-31 杭州中美华东制药有限公司 一种芦可替尼组合物及其制备方法
WO2023057999A1 (en) * 2021-10-08 2023-04-13 Eptiva Therapeutics Ltd. Calcitriol or calcitriol analogues for treating peripheral neuropathic pain disorders
US12642802B2 (en) 2021-12-03 2026-06-02 Incyte Corporation Topical formulations of ruxolitinib with an organic amine pH adjusting agent for treatment of skin diseases
WO2023102559A1 (en) * 2021-12-03 2023-06-08 Incyte Corporation Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases
WO2024243225A1 (en) * 2023-05-21 2024-11-28 Incyte Corporation Topical ruxolitinib foam
KR20260035991A (ko) * 2024-08-26 2026-03-13 인사이트 코포레이션 룩소리티닙의 약학적으로 허용 가능한 염의 국소 피부 제형

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1173703C (zh) 1999-04-23 2004-11-03 里奥药物制品有限公司 药物组合物
PL374777A1 (pl) 2002-12-17 2005-10-31 Galderma Sa Kompozycje farmaceutyczne, zawierające połączeniekalcytriolu i propionianu klobetazolu
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
JP2015528501A (ja) * 2012-09-12 2015-09-28 ライジェル ファーマシューティカルズ, インコーポレイテッド 白斑の治療法
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
CR20190156A (es) 2013-05-17 2019-05-16 Incyte Corp Derivados de bipirazol como inhibidores jak
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
WO2019191679A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Biomarkers for inflammatory skin disease
WO2020222187A1 (en) * 2019-05-01 2020-11-05 Clexio Biosciences Ltd. Finished fibrous structures and methods of their use and preparation
EP4200275A2 (en) * 2020-08-21 2023-06-28 Sitryx Therapeutics Limited Fumarate derivatives and their medical use

Also Published As

Publication number Publication date
US20250049817A1 (en) 2025-02-13
LT4255442T (lt) 2025-07-25
TW202237125A (zh) 2022-10-01
HUE071614T2 (hu) 2025-09-28
US12005067B2 (en) 2024-06-11
PT4255442T (pt) 2025-05-19
CA3204186A1 (en) 2022-06-09
ES3025481T3 (en) 2025-06-09
MD4255442T2 (ro) 2025-08-31
KR20230128472A (ko) 2023-09-05
SI4255442T1 (sl) 2025-06-30
DK4255442T3 (da) 2025-05-19
RS66785B1 (sr) 2025-06-30
CL2023001603A1 (es) 2024-05-24
WO2022120131A1 (en) 2022-06-09
FI4255442T3 (fi) 2025-05-16
HRP20250528T1 (hr) 2025-06-20
AU2021390533A1 (en) 2023-06-29
ZA202306521B (en) 2024-04-24
JP7847143B2 (ja) 2026-04-16
EP4570321A3 (en) 2025-08-20
IL303410A (en) 2023-08-01
EP4255442B1 (en) 2025-03-19
EP4570321A2 (en) 2025-06-18
MX2023006638A (es) 2023-08-22
US20220202834A1 (en) 2022-06-30
SMT202500205T1 (it) 2025-07-22
EP4255442A1 (en) 2023-10-11
MA62453B1 (fr) 2025-06-30
JP2023552424A (ja) 2023-12-15

Similar Documents

Publication Publication Date Title
LT4255442T (lt) Jak inhibitorius su vitamino d analogu, skirtas odos ligų gydymui
IL289405A (en) Personalized treatment of eye diseases
EP4525871A4 (en) TREATMENT OF DEPRESSION
HUE067909T2 (hu) Pirimidin JAK-inhibitorok bõrbetegségek kezelésére
IL290637A (en) Topical treatment of vitiligo by jak inhibitor
IL320805B1 (en) Therapeutic uses of tirzepatide
CA223399S (en) Skin treatment tip
EP4103195A4 (en) TREATMENT OF INFECTIOUS DISEASES
EP4267196A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
EP4090420A4 (en) PHOTOTHERAPEUTIC TREATMENT OF SKIN DISEASES
EP4355355A4 (en) TREATMENT OF PLIN1-ASSOCIATED DISEASES AND DISORDERS
IL304628A (en) Treatment of skin disorders
GB202001353D0 (en) Treatment of skin conditions
HK40101150A (en) Jak inhibitor with a vitamin d analog for treatment of skin diseases
LT4329725T (lt) Izociklosporinas a, skirtas vietiniam akių ligų gydymui
EP4193995A4 (en) USE OF BTK INHIBITORS TO TREAT DISEASES
EP4157233A4 (en) TREATMENT OF PSORIASIS AND INFLAMMATORY SKIN DISEASES
GB202315831D0 (en) Treatment of skin disease
CA234057S (en) Skin treatment tip
CA240253S (en) Skin treatment tip
GB202316556D0 (en) Therapy of resistant diseases
GB202503453D0 (en) Compounds for the treatment of skin diseases
GB202403324D0 (en) Compounds for the treatment of skin diseases
HK40084366A (en) Treatment of panx1 associates diseases
HK40090647A (en) Treatment for psoriasis and skin inflammatory diseases